Weekly Research Analysts’ Ratings Changes for Hemab Therapeutics (COAG)

A number of firms have modified their ratings and price targets on shares of Hemab Therapeutics (NASDAQ: COAG) recently:

• 5/27/2026 – Hemab Therapeutics was upgraded by Zacks Research to “hold”.
• 5/26/2026 – Hemab Therapeutics is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $39.00 price target on the stock.
• 5/26/2026 – Hemab Therapeutics is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $36.00 price target on the stock.
• 5/26/2026 – Hemab Therapeutics is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $39.00 price target on the stock.
• 5/26/2026 – Hemab Therapeutics is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $36.00 price target on the stock.
• 5/26/2026 – Hemab Therapeutics is now covered by Evercore Inc. They set an “outperform” rating and a $50.00 price target on the stock.
• 5/26/2026 – Hemab Therapeutics is now covered by Wedbush. They set an “outperform” rating and a $42.00 price target on the stock.
• 5/9/2026 – Hemab Therapeutics was upgraded by Wall Street Zen to “hold”.

Insider Buying and Selling at Hemab Therapeutics

In other news, major shareholder Ra Capital Management, L.P. acquired 3,802 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were acquired at an average price of $24.97 per share, with a total value of $94,935.94. Following the acquisition, the insider directly owned 6,375,972 shares in the company, valued at approximately $159,208,020.84. The trade was a 0.06% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have acquired 2,902,872 shares of company stock worth $53,769,784 over the last 90 days.

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.